NCT05103241View on ClinicalTrials.gov

A Phase I Mass Balance Study of [14C]GP681 in Healthy Chinese Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 26, 2021

Primary Completion Date

November 22, 2021

Study Completion Date

November 22, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

[14C] GP681

40 mg suspension containing 100μCi of \[14C\]GP681

Trial Locations (1)

200031

Shanghai Xuhui Central Hospital, Shanghai

Sponsors
All Listed Sponsors
lead

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

INDUSTRY